| Literature DB >> 34042299 |
Christopher J Kotarsky1,2, Nathaniel R Johnson1, Sean J Mahoney1, Steven L Mitchell1,3, Regina L Schimek1, Sherri N Stastny1, Kyle J Hackney1.
Abstract
The purpose of this study was to determine whether time-restricted eating (TRE), also known as time-restricted feeding, was an effective dietary strategy for reducing fat mass and preserving fat-free mass while evaluating changes in cardiometabolic biomarkers, hormones, muscle performance, energy intake, and macronutrient intake after aerobic and resistance exercise training in physically inactive and overweight or obese adults. This study was a randomized, controlled trial. Overweight and obese adults (mean ± SD; age: 44 ± 7 years; body mass index [BMI]: 29.6 ± 2.6 kg/m2 ; female: 85.7%) were randomly assigned to a TRE or normal eating (NE) dietary strategy group. The TRE participants consumed all calories between 12:00 p.m. and 8:00 p.m., whereas NE participants maintained their dietary habits. Both groups completed 8 weeks of aerobic exercise and supervised resistance training. Body composition, muscle performance, energy intake, macronutrient intake, physical activity, and physiological variables were assessed. A total of 21 participants completed the study (NE: n = 10; TRE: n = 11). A mild energy restriction was observed for TRE (~300 kcal/day, 14.5%) and NE (~250 kcal/day, 11.4%). Losses of total body mass were significantly greater for TRE (3.3%) relative to NE (0.2%) pre- to post-intervention, of which TRE had significantly greater losses of fat mass (9.0%) compared to NE (3.3%). Lean mass increased during the intervention for both TRE (0.6%) and NE (1.9%), with no group differences. These data support the use of TRE and concurrent exercise training as a short-term dietary strategy for reducing fat mass and increasing lean mass in overweight and obese adults.Entities:
Keywords: aerobic training; intermittent fasting; obesity; resistance training; weight loss
Mesh:
Year: 2021 PMID: 34042299 PMCID: PMC8157764 DOI: 10.14814/phy2.14868
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
FIGURE 1Subject screening and completion flowchart
Participant characteristics at baseline
| NE ( | TRE ( |
| |
|---|---|---|---|
| Age (years) | 44 ± 2 | 45 ± 3 | 0.739 |
| Body mass (kg) | 83 ± 3 | 82 ± 3 | 0.823 |
| Height (cm) | 168 ± 3 | 166 ± 2 | 0.599 |
| BMI (kg/m2) | 29.4 ± 0.8 | 29.8 ± 0.8 | 0.742 |
| Hip circumference (cm) | 108.4 ± 2.9 | 109.2 ± 1.6 | 0.806 |
| Waist circumference (cm) | 95.3 ± 3.0 | 98.0 ± 1.9 | 0.445 |
Data are presented as mean ± standard error; p values are from one‐way analysis of variance.
Abbreviations: BMI, body mass index; NE, normal eating; TRE, time‐restricted eating.
Anthropometrics
| Group | Pre‐intervention | Post‐intervention | Δ | ES ( |
|
|
|
|---|---|---|---|---|---|---|---|
| Body mass (kg) | |||||||
| NE | 83 ± 3 | 83 ± 3 | 0 | −0.04 | 0.641 |
|
|
| TRE | 82 ± 3 | 79 ± 3 | −3 | −0.30 | |||
| BMI (kg/m2) | |||||||
| NE | 29.4 ± 0.8 | 29.3 ± 0.9 | −0.1 | −0.04 | 0.966 |
|
|
| TRE | 29.8 ± 0.8 | 28.8 ± 0.8 | −1.0 | −0.36 | |||
| Hip circumference (cm) | |||||||
| NE | 108.4 ± 2.9 | 108.9 ± 2.7 | 0.5 | 0.07 | 0.886 | 0.328 | 0.079 |
| TRE | 109.2 ± 1.6 | 107.2 ± 1.7 | −2.0 | −0.35 | |||
| Waist circumference (cm) | |||||||
| NE | 95.3 ± 3.0 | 92.3 ± 3.0 | −3.0 | −0.32 | 0.626 |
| 0.493 |
| TRE | 98.0 ± 1.9 | 92.8 ± 2.2 | −5.2 | −0.77 | |||
Data are presented as mean ± standard error; p values are from repeated‐measures analysis of variance. The bold emphasis was used to indicate (bring attention to) statistical significance within the table.
Abbreviations: BMI, body mass index; ES, effect size; I, interaction; NE, normal eating; TRE, time‐restricted eating.
Physical activity
| Group | Week 2 | Week 5 | Week 8 |
|
|
|
|---|---|---|---|---|---|---|
| Sedentary time (min/day) | ||||||
| NE | 2985 ± 184 | 2992 ± 192 | 2767 ± 295 | 0.648 | 0.464 | 0.252 |
| TRE | 2905 ± 233 | 2653 ± 164 | 2839 ± 113 | |||
| Light PA (min/day) | ||||||
| NE | 2429 ± 198 | 2559 ± 200 | 2296 ± 264 | 0.455 | 0.439 | 0.251 |
| TRE | 2315 ± 101 | 2200 ± 157 | 2246 ± 116 | |||
| MV PA (min/day) | ||||||
| NE | 310 ± 38 | 390 ± 51 | 341 ± 43 | 0.952 |
| 0.782 |
| TRE | 326 ± 33 | 384 ± 51 | 326 ± 39 | |||
| Steps (#/day) | ||||||
| NE | 7541 ± 782 | 8781 ± 842 | 8039 ± 686 | 0.686 |
| 0.299 |
| TRE | 8116 ± 828 | 9773 ± 1186 | 7929 ± 835 | |||
Data are presented as mean ± SE. p values are from repeated‐measures ANOVA. Bold emphasis was used to indicated (bring attention to) statistical significance (i.e., an alpha level of 0.05) within the tables.
Abbreviations: I, Interaction; MV, moderate‐to‐vigorous; NE, normal eating; PA, physical activity; TRE, time‐restricted eating.
FIGURE 2Average time spent in moderate‐to‐vigorous (MV) physical activity (PA). Results display (time‐restricted eating [TRE]: n = 11; normal eating [NE]: n = 10) average minutes (mean ± SE) at Weeks 2, 5, and 8. Brackets indicate a significant change within groups (i.e., time main effects), with no significant differences between groups
Dietary intake
| Group | Pre‐intervention | Week 1 | Week 4 | Week 7 | Δ |
|
|
|
|---|---|---|---|---|---|---|---|---|
| Energy (kcal) | ||||||||
| NE | 2227 ± 177 | 1985 ± 158 | 1921 ± 158 | 1974 ± 245 | −253 | 0.467 |
| 0.510 |
| TRE | 2112 ± 179 | 1640 ± 159 | 1856 ± 208 | 1806 ± 180 | −306 | |||
| Protein | ||||||||
| (g) | ||||||||
| NE | 76 ± 8 | 71 ± 6 | 76 ± 9 | 70 ± 10 | −6 | 0.899 | 0.088 | 0.611 |
| TRE | 83 ± 9 | 68 ± 6 | 73 ± 8 | 73 ± 7 | −10 | |||
| (%) | ||||||||
| NE | 14 ± 1 | 14 ± 1 | 16 ± 1 | 14 ± 1 | 0 | 0.106 | 0.208 | 0.347 |
| TRE | 16 ± 1 | 17 ± 1 | 16 ± 1 | 16 ± 1 | 0 | |||
| (g/kg) | ||||||||
| NE | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.8 ± 0.1 | −0.1 | 0.624 | 0.111 | 0.532 |
| TRE | 1.0 ± 0.1 | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 | −0.1 | |||
| Carbohydrate | ||||||||
| (g) | ||||||||
| NE | 266 ± 18 | 241 ± 19 | 236 ± 19 | 235 ± 26 | −31 | 0.209 |
| 0.240 |
| TRE | 255 ± 29 | 177 ± 24 | 202 ± 22 | 190 ± 28 | −65 | |||
| (%) | ||||||||
| NE | 49 ± 4 | 50 ± 3 | 50 ± 3 | 49 ± 3 | 0 | 0.107 | 0.336 | 0.316 |
| TRE | 48 ± 3 | 43 ± 3 | 44 ± 3 | 41 ± 2 | −7 | |||
| (g/kg) | ||||||||
| NE | 3.2 ± 0.2 | 2.9 ± 0.2 | 2.9 ± 0.2 | 2.8 ± 0.2 | −0.4 | 0.230 |
| 0.215 |
| TRE | 3.1 ± 0.3 | 2.2 ± 0.3 | 2.5 ± 0.3 | 2.4 ± 0.3 | −0.7 | |||
| Fat | ||||||||
| (g) | ||||||||
| NE | 83 ± 10 | 76 ± 9 | 71 ± 8 | 77 ± 11 | −6 | 0.961 | 0.407 | 0.602 |
| TRE | 82 ± 9 | 68 ± 7 | 79 ± 13 | 81 ± 8 | −1 | |||
| (%) | ||||||||
| NE | 33 ± 3 | 34 ± 2 | 33 ± 2 | 34 ± 2 | 1 | 0.056 | 0.299 | 0.785 |
| TRE | 35 ± 2 | 37 ± 2 | 37 ± 2 | 41 ± 1 | 6 | |||
| (g/kg) | ||||||||
| NE | 1.0 ± 0.1 | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.9 ± 0.1 | −0.1 | 0.719 | 0.316 | 0.493 |
| TRE | 1.0 ± 0.1 | 0.8 ± 0.1 | 1.0 ± 0.2 | 1.0 ± 0.1 | 0.0 | |||
Data are presented as mean ± standard error; p values are from repeated‐measures analysis of variance. The bold emphasis was used to indicate (bring attention to) statistical significance within the table.
Abbreviations: I, interaction; NE, normal eating; TRE, time‐restricted eating.
FIGURE 3Body composition changes. Results display (time‐restricted eating [TRE]: n = 11; normal eating [NE]: n = 10) delta differences (mean ± SE) between pre‐ and post‐intervention. Asterisks with brackets indicate a significant difference in TRE relative to NE (i.e., interaction effect). Brackets indicate a significant change within groups (i.e., time main effects), with no significant differences between groups. FM, fat mass; LM, lean mass; RFM, region fat mass; RLM, region lean mass; TBM, total body mass; TFM, tissue fat mass; TM, tissue mass; VFM, visceral fat mass
Body composition
| Group | Pre | Post | Δ | ES (d) |
|
|
|
|---|---|---|---|---|---|---|---|
| Tissue fat mass (%) | |||||||
| NE | 41 ± 2 | 40 ± 2 | −1 | −0.20 | 0.902 |
|
|
| TRE | 41 ± 2 | 39 ± 2 | −2 | −0.43 | |||
| Region fat mass (%) | |||||||
| NE | 40 ± 2 | 38 ± 2 | −2 | −0.20 | 0.887 |
|
|
| TRE | 40 ± 2 | 37 ± 2 | −3 | −0.43 | |||
| Region lean mass (%) | |||||||
| NE | 57 ± 2 | 59 ± 2 | 2 | 0.20 | 0.917 |
|
|
| TRE | 57 ± 2 | 59 ± 2 | 2 | 0.44 | |||
| Tissue mass (kg) | |||||||
| NE | 80 ± 3 | 80 ± 3 | 0 | −0.02 | 0.612 |
|
|
| TRE | 79 ± 2 | 77 ± 3 | −2 | −0.32 | |||
| Fat mass (kg) | |||||||
| NE | 33 ± 2 | 32 ± 2 | −1 | −0.14 | 0.746 |
|
|
| TRE | 33 ± 2 | 30 ± 2 | −3 | −0.44 | |||
| Lean mass (kg) | |||||||
| NE | 47 ± 2 | 48 ± 2 | 1 | 0.12 | 0.707 |
| 0.292 |
| TRE | 47 ± 2 | 47 ± 2 | 0 | 0.06 | |||
| Total body mass (kg) | |||||||
| NE | 83 ± 3 | 82 ± 3 | −1 | −0.02 | 0.624 |
|
|
| TRE | 82 ± 3 | 79 ± 3 | −3 | −0.32 | |||
| Visceral fat mass (kg) | |||||||
| NE | 1.07 ± 0.17 | 1.00 ± 0.15 | −0.07 | −0.14 | 0.700 |
| 0.261 |
| TRE | 1.01 ± 0.18 | 0.87 ± 0.16 | −0.14 | −0.25 | |||
| BMC (kg) | |||||||
| NE | 2.58 ± 0.13 | 2.57 ± 0.12 | −0.01 | −0.03 | 0.915 | 0.119 | 0.221 |
| TRE | 2.60 ± 0.11 | 2.58 ± 0.11 | −0.02 | −0.05 | |||
| BMD (g/cm2) | |||||||
| NE | 1.23 ± 0.04 | 1.24 ± 0.04 | 0.01 | 0.09 | 0.751 | 0.387 | 0.161 |
| TRE | 1.26 ± 0.04 | 1.25 ± 0.04 | −0.01 | −0.10 | |||
Data are presented as mean ± SE. p values are from repeated‐measures ANOVA. Bold emphasis was used to indicated (bring attention to) statistical significance (i.e., an alpha level of 0.05) within the tables.
Abbreviations: BMC, bone mineral content; BMD, bone mineral density; ES, effect size; I, Interaction; NE, normal eating; TRE, time‐restricted eating.
Muscle performance
| Group | Pre‐intervention | Post‐intervention | Δ | ES ( |
|
|
|
|---|---|---|---|---|---|---|---|
| Handgrip (kg) | |||||||
| NE | 43 ± 4 | 44 ± 4 | 1 | 0.12 | 0.601 | 0.573 | 0.341 |
| TRE | 41 ± 3 | 41 ± 3 | 0 | −0.04 | |||
| KE STR PT (Nm) | |||||||
| NE | 138 ± 7 | 156 ± 7 | 18 | 0.83 | 0.523 | 0.220 |
|
| TRE | 140 ± 15 | 134 ± 13 | −6 | −0.14 | |||
| KF STR PT (Nm) | |||||||
| NE | 82 ± 6 | 100 ± 5 | 18 | 1.01 | 0.677 |
| 0.636 |
| TRE | 80 ± 8 | 95 ± 7 | 15 | 0.61 | |||
| KE END TW (J) | |||||||
| NE | 1456 ± 121 | 1467 ± 152 | 11 | 0.02 | 0.265 | 0.383 | 0.301 |
| TRE | 1314 ± 144 | 1190 ± 126 | −124 | −0.28 | |||
| KF END TW (J) | |||||||
| NE | 1109 ± 128 | 1307 ± 98 | 198 | 0.55 | 0.993 |
| 0.773 |
| TRE | 1087 ± 120 | 1325 ± 79 | 238 | 0.71 | |||
| PF STR PT (Nm) | |||||||
| NE | 86 ± 6 | 83 ± 5 | −3 | −0.16 | 0.109 | 0.952 | 0.379 |
| TRE | 68 ± 6 | 71 ± 9 | 3 | 0.13 | |||
| DF STR PT (Nm) | |||||||
| NE | 20 ± 3 | 25 ± 2 | 5 | 0.72 | 0.740 |
| 0.870 |
| TRE | 21 ± 3 | 26 ± 2 | 5 | 0.58 | |||
| PF END TW (J) | |||||||
| NE | 760 ± 80 | 698 ± 82 | −62 | −0.24 | 0.231 | 0.082 | 0.802 |
| TRE | 628 ± 84 | 547 ± 94 | −81 | −0.27 | |||
| DF END TW (J) | |||||||
| NE | 110 ± 34 | 231 ± 30 | 121 | 1.19 | 0.730 |
| 0.159 |
| TRE | 161 ± 45 | 212 ± 30 | 51 | 0.40 | |||
Data are presented as mean ± standard error; p values are from repeated‐measures analysis of variance. The bold emphasis was used to indicate (bring attention to) statistical significance within the table.
Abbreviations: DF, dorsiflexion; END, endurance; ES, effect size; I, interaction; KE, knee extension; KF, knee flexion; NE, normal eating; PF, plantar flexion; PT, peak torque; STR, strength; TRE, time‐restricted eating; TW, total work.
Cardiorespiratory performance and hemodynamics
| Group | Pre | Post | Δ | ES (d) |
|
|
|
|---|---|---|---|---|---|---|---|
| Systolic BP | |||||||
| NE | 120 ± 2 | 118 ± 3 | −2 | −0.20 | 0.921 | 0.150 | 0.388 |
| TRE | 122 ± 3 | 116 ± 3 | −6 | −0.69 | |||
| Diastolic BP | |||||||
| NE | 83 ± 1 | 79 ± 2 | −4 | −0.87 | 0.820 | 0.107 | 0.168 |
| TRE | 81 ± 2 | 80 ± 2 | −1 | −0.07 | |||
| Resting HR | |||||||
| NE | 75 ± 2 | 69 ± 3 | −6 | −0.72 | 0.654 |
| 0.064 |
| TRE | 75 ± 2 | 66 ± 2 | −9 | −1.21 | |||
| Step HR | |||||||
| NE | 125 ± 6 | 112 ± 7 | −13 | −0.63 | 0.346 |
| 0.205 |
| TRE | 122 ± 5 | 100 ± 6 | −22 | −1.32 | |||
Data are presented as mean ± SE. p values are from repeated‐measures ANOVA. Bold emphasis was used to indicated (bring attention to) statistical significance (i.e., an alpha level of 0.05) within the tables.
Abbreviations: BP, blood pressure; HR, heart rate; ES, effect size; I, Interaction; NE, normal eating; TRE, time‐restricted eating.
Resting cardiometabolic profiles
| Group | Pre‐intervention | Post‐intervention | Δ | ES ( |
|
|
|
|---|---|---|---|---|---|---|---|
| Insulin (µIU/ml) | |||||||
| NE | 13 ± 2 | 10 ± 1 | −3 | −0.51 | 0.361 | 0.092 | 0.934 |
| TRE | 11 ± 1 | 9 ± 2 | −2 | −0.44 | |||
| hsCRP (mg/L) | |||||||
| NE | 1.0 ± 0.3 | 1.3 ± 0.3 | 0.3 | 0.29 | 0.114 | 0.694 | 0.197 |
| TRE | 2.9 ± 0.9 | 2.4 ± 0.8 | −0.5 | −0.17 | |||
| HbA1c (%) | |||||||
| NE | 4.7 ± 0.2 | 4.3 ± 0.2 | −0.4 | −0.70 | 0.816 | 0.055 | 0.142 |
| TRE | 4.6 ± 0.2 | 4.6 ± 0.3 | 0.0 | −0.07 | |||
| Cholesterol (mg/dl) | |||||||
| NE | 200 ± 12 | 199 ± 12 | −1 | −0.01 | 0.800 | 0.804 | 0.655 |
| TRE | 202 ± 12 | 206 ± 10 | 4 | 0.11 | |||
| HDL (mg/dl) | |||||||
| NE | 55 ± 6 | 55 ± 4 | 0 | 0.00 | 0.966 | 0.589 | 0.859 |
| TRE | 55 ± 3 | 54 ± 3 | −1 | −0.43 | |||
Data are presented as mean ± standard error; p values are from repeated‐measures analysis of variance.
Abbreviations: ES, effect size; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein cholesterol; hsCRP, high‐sensitivity C‐reactive protein; I, interaction; NE, normal eating; TRE, time‐restricted eating.
Resting hormonal profiles (female participants only)
| Group | Pre‐intervention | Post‐intervention | Δ | ES ( |
|
|
|
|---|---|---|---|---|---|---|---|
| Estradiol (pg/ml) | |||||||
| NE | 0.8 ± 0.2 | 1.0 ± 0.2 | 0.1 | 0.20 | 0.467 | 0.228 | 0.700 |
| TRE | 0.7 ± 0.1 | 0.9 ± 0.1 | 0.2 | 0.72 | |||
| Progesterone (pg/ml) | |||||||
| NE | 26 ± 12 | 17 ± 6 | −9 | −0.32 | 0.625 | 0.181 | 0.676 |
| TRE | 26 ± 12 | 27 ± 13 | 1 | 0.02 | |||
| Testosterone (pg/ml) | |||||||
| NE | 23 ± 3 | 20 ± 3 | −3 | −0.33 | 0.433 | 0.090 | 0.791 |
| TRE | 27 ± 7 | 25 ± 7 | −2 | −0.15 | |||
| DHEAS (ng/ml) | |||||||
| NE | 4.6 ± 1.2 | 4.2 ± 0.7 | −0.4 | −0.13 | 0.631 | 0.589 | 0.165 |
| TRE | 4.7 ± 1.0 | 5.6 ± 1.4 | 0.9 | 0.24 | |||
| Cortisol (ng/ml) | |||||||
| NE | 5.9 ± 0.8 | 5.1 ± 0.5 | −0.8 | −0.38 | 0.950 | 0.664 | 0.418 |
| TRE | 5.4 ± 1.0 | 5.7 ± 0.6 | 0.2 | 0.10 | |||
Data are presented as mean ± standard error; p values are from repeated‐measures analysis of variance.
Abbreviations: DHEAS, dehydroepiandrosterone sulfate; ES, effect size; I, interaction; NE, normal eating; TRE, time‐restricted eating.